TransCode Therapeutics (RNAZ) said Thursday that the Safety Review Committee, monitoring its phase 1 clinical study, has unanimously approved to open a fourth group of patients based on "favorable" safety data from the three patients in group 3 for multiple metastatic cancers treatment.
The company is evaluating TTX-MC138 therapeutic candidate in its phase 1 clinical study to treat multiple metastatic cancers through antisense technology, it said. The dose for the fourth group will be roughly 50% higher than the dose given to the third group.
TransCode said it treated nine patients in the first three groups with TTX-MC138 and there were "no significant safety or dose limiting toxicities" seen during the first three groups, adding that six participants remain on trial for continued treatment.
The committee has also approved the enrollment of further participants in the third group to build upon the safety profile of TTX-MC138, TransCode added.
Shares of the company fell more than 6% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.